Matter Bio is a longevity holding company focused on preserving genome integrity by addressing mutations, structural variations, and epigenetic drift that accumulate with age. The company employs a team of scientists to develop targeted interventions that counteract genomic information loss, aiming to slow and potentially reverse key drivers of aging.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Aging is characterized by the accumulation of damage to the genome, including mutations, structural variations, and epigenetic drift. This genomic instability leads to cellular dysfunction and age-related diseases. Current approaches to address aging often lack direct mechanisms for repairing or removing cells with corrupted DNA.
Solution
Matter Bio is developing targeted interventions to protect cells from genomic damage and eliminate cells with corrupted DNA. The company focuses on enhancing cellular DNA damage repair mechanisms and removing cancerous cells to prevent and treat age-related diseases. By addressing the root causes of genomic instability, Matter Bio aims to slow down and potentially reverse key drivers of aging, ultimately extending lifespan.
Target Audience
The primary target audience includes individuals and organizations interested in longevity, genetics, computational biology, and cancer research, as well as those seeking to prevent and treat age-related diseases.
Features
- Enhances cellular DNA damage repair mechanisms to maintain genome integrity.
- Develops methods for removing cells with corrupted DNA, including cancerous cells.
- Focuses on addressing mutations, structural variations, and epigenetic drift.
- Aims to prevent and treat a wide array of age-related diseases.